MEI Pharma Stock Price, News & Analysis (NASDAQ:MEIP)

$2.19 +0.09 (+4.29 %)
(As of 02/23/2018 02:54 PM ET)
Previous Close$2.19
Today's Range$2.13 - $2.21
52-Week Range$1.48 - $3.26
Volume46,200 shs
Average Volume116,087 shs
Market Capitalization$80.92 million
P/E Ratio-4.13
Dividend YieldN/A
Beta2.1

About MEI Pharma (NASDAQ:MEIP)

MEI Pharma logoMEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Receive MEIP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:MEIP
CUSIPN/A
Phone+1-858-7926300

Debt

Debt-to-Equity RatioN/A
Current Ratio8.31%
Quick Ratio8.31%

Price-To-Earnings

Trailing P/E Ratio-4.13207547169811
Forward P/E Ratio-2.31
P/E GrowthN/A

Sales & Book Value

Annual Sales$23.25 million
Price / Sales3.49
Cash Flow$0.08 per share
Price / Cash28.08
Book Value$1.03 per share
Price / Book2.13

Profitability

Trailing EPS($0.53)
Net Income$2.67 million
Net Margins-354.10%
Return on Equity-42.23%
Return on Assets-38.25%

Miscellaneous

Employees25
Outstanding Shares37,050,000

MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

How were MEI Pharma's earnings last quarter?

MEI Pharma Inc (NASDAQ:MEIP) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.03) by $0.01. The business had revenue of $4.51 million for the quarter, compared to analysts' expectations of $5 million. MEI Pharma had a negative return on equity of 42.23% and a negative net margin of 354.10%. View MEI Pharma's Earnings History.

Where is MEI Pharma's stock going? Where will MEI Pharma's stock price be in 2018?

2 brokerages have issued 1-year price objectives for MEI Pharma's shares. Their forecasts range from $6.50 to $7.00. On average, they expect MEI Pharma's stock price to reach $6.75 in the next year. View Analyst Ratings for MEI Pharma.

What are Wall Street analysts saying about MEI Pharma stock?

Here are some recent quotes from research analysts about MEI Pharma stock:

  • 1. According to Zacks Investment Research, "MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. " (2/10/2018)
  • 2. Cann analysts commented, "MEI Pharma’s F2Q loss per share of $0.16 was higher than our estimated $0.09, due to operating expenses of $6.5 million, or 50.2% higher than our estimated $4.3 million. The higher than estimated expenses stemmed primarily from higher R&D expenses and costs associated with collaboration revenues. Higher R&D expenses are attributed to voruciclib expenses and increased R&D for ME-401. Our outlook for FY2019-23 revenue remains basically unchanged. Our FY2018 loss per share foreacast is being increased by 12% to account for higher anticipated R&D expense and costs associated with collaboration revenue." (2/8/2018)

Who are some of MEI Pharma's key competitors?

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the folowing people:

  • Christine Anna White M.D., Independent Chairman of the Board (Age 65)
  • Daniel P. Gold Ph.D., President, Chief Executive Officer, Director (Age 62)
  • Brian G. Drazba, Chief Financial Officer, Secretary (Age 54)
  • David M. Urso, Senior Vice President of Corporate Development, General Counsel (Age 52)
  • Robert D. Mass M.D., Chief Medical Officer (Age 60)
  • Charles V. Baltic III, Independent Director (Age 55)
  • Kevan E. Clemens Ph.D., Independent Director (Age 72)
  • Nicholas R. Glover Ph.D., Independent Director (Age 48)
  • Thomas C. Reynolds M.D. Ph.D., Independent Director (Age 57)
  • William Dodge Rueckert, Independent Director (Age 64)

Who owns MEI Pharma stock?

MEI Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.44%), Acadian Asset Management LLC (1.33%) and Deutsche Bank AG (0.62%). View Institutional Ownership Trends for MEI Pharma.

Who sold MEI Pharma stock? Who is selling MEI Pharma stock?

MEI Pharma's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View Insider Buying and Selling for MEI Pharma.

Who bought MEI Pharma stock? Who is buying MEI Pharma stock?

MEI Pharma's stock was bought by a variety of institutional investors in the last quarter, including Deutsche Bank AG and Renaissance Technologies LLC. View Insider Buying and Selling for MEI Pharma.

How do I buy MEI Pharma stock?

Shares of MEI Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MEI Pharma's stock price today?

One share of MEI Pharma stock can currently be purchased for approximately $2.19.

How big of a company is MEI Pharma?

MEI Pharma has a market capitalization of $80.92 million and generates $23.25 million in revenue each year. The company earns $2.67 million in net income (profit) each year or ($0.53) on an earnings per share basis. MEI Pharma employs 25 workers across the globe.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 3611 Valley Centre Dr Ste 500, SAN DIEGO, CA 92130-3324, United States. The company can be reached via phone at +1-858-7926300 or via email at [email protected]


MarketBeat Community Rating for MEI Pharma (MEIP)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  284
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MEI Pharma (NASDAQ:MEIP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.75$6.75$6.75$6.75
Price Target Upside: 200.00% upside209.63% upside193.48% upside193.48% upside

MEI Pharma (NASDAQ:MEIP) Consensus Price Target History

Price Target History for MEI Pharma (NASDAQ:MEIP)

MEI Pharma (NASDAQ:MEIP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018CannReiterated RatingBuyMediumView Rating Details
1/8/2018OppenheimerSet Price TargetBuy$7.00LowView Rating Details
8/2/2016WedbushReiterated RatingNeutral$2.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

MEI Pharma (NASDAQ:MEIP) Earnings History and Estimates Chart

Earnings by Quarter for MEI Pharma (NASDAQ:MEIP)

MEI Pharma (NASDAQ MEIP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q1 2018($0.17)($0.24)$0.70 million$0.28 millionViewN/AView Earnings Details
9/5/2017Q4 2017($0.15)($0.12)$0.60 million$0.45 millionViewListenView Earnings Details
5/4/2017Q3 2017($0.03)($0.02)$5.00 million$4.51 millionViewN/AView Earnings Details
2/8/2017Q217($0.29)$0.32$1.25 million$17.20 millionViewN/AView Earnings Details
11/8/2016Q1 2017($0.14)($0.12)$0.63 million$1.10 millionViewN/AView Earnings Details
9/6/2016Q4 2016($0.20)($0.17)ViewN/AView Earnings Details
5/5/2016Q3 2016($0.15)($0.16)ViewN/AView Earnings Details
2/5/2016Q2 2016($0.17)($0.15)ViewN/AView Earnings Details
11/6/2015Q1 2016($0.19)($0.13)ViewN/AView Earnings Details
9/2/2015Q4 2015($0.23)($0.17)ViewN/AView Earnings Details
5/7/2015Q3 2015($0.29)($0.27)ViewN/AView Earnings Details
9/9/2014Q4 2014($0.37)($0.40)ViewN/AView Earnings Details
5/8/2014Q3 2014($0.37)($0.34)ViewN/AView Earnings Details
2/11/2014Q2 2014($0.37)($0.32)ViewN/AView Earnings Details
11/8/2013Q1 2014($0.37)($0.29)ViewN/AView Earnings Details
9/18/2013Q4 2013($0.37)($0.19)ViewN/AView Earnings Details
5/9/2013Q3 2013($0.37)($0.18)ViewN/AView Earnings Details
2/12/2013Q2 2013($0.37)($0.50)ViewN/AView Earnings Details
11/13/2012Q1 2013($2.22)($4.20)ViewN/AView Earnings Details
9/18/2012Q4 2012($2.22)($4.26)ViewN/AView Earnings Details
5/15/2012Q3 2012($2.22)($5.58)ViewN/AView Earnings Details
2/9/2012Q2 2012($0.78)ViewN/AView Earnings Details
11/14/2011Q1 2012($1.46)ViewN/AView Earnings Details
9/29/2011Q4 2011($0.81)ViewN/AView Earnings Details
5/16/2011Q3 2011($1.06)ViewN/AView Earnings Details
9/1/2009Q4 2009($4.20)ViewN/AView Earnings Details
5/7/2008Q3 2008($3.60)($3.00)ViewN/AView Earnings Details
2/8/2008Q2 2008($3.60)($1.80)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

MEI Pharma (NASDAQ:MEIP) Earnings Estimates

2018 EPS Consensus Estimate: ($0.57)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.18)($0.18)($0.18)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.13)($0.13)($0.13)
Q4 20181($0.17)($0.17)($0.17)
Q1 20191($0.29)($0.29)($0.29)
Q2 20191($0.32)($0.32)($0.32)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for MEI Pharma (NASDAQ:MEIP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

MEI Pharma (NASDAQ MEIP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.25%
Institutional Ownership Percentage: 21.51%
Insider Trades by Quarter for MEI Pharma (NASDAQ:MEIP)
Institutional Ownership by Quarter for MEI Pharma (NASDAQ:MEIP)

MEI Pharma (NASDAQ MEIP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/27/2017Charles V Baltic IIIDirectorBuy11,000$2.25$24,750.0013,250View SEC Filing  
11/9/2015Vivo Ventures Vii, LlcMajor ShareholderSell390,572$1.84$718,652.48View SEC Filing  
1/21/2015Charles V Baltic IIIDirectorBuy5,000$3.81$19,050.00View SEC Filing  
12/9/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell79,085$6.01$475,300.85View SEC Filing  
12/8/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell9,004$6.05$54,474.20View SEC Filing  
6/30/2014Charles V Baltic IIIDirectorBuy2,000$6.56$13,120.00View SEC Filing  
10/29/2013Vivo Ventures Vii, LlcMajor ShareholderSell299,609$8.21$2,459,789.89View SEC Filing  
10/2/2013Vivo Ventures Vii, LlcMajor ShareholderSell581,646$10.16$5,909,523.36View SEC Filing  
8/16/2013Charles V Baltic IIIDirectorBuy2,600$6.82$17,732.00View SEC Filing  
6/28/2013Vivo Ventures Vii, LlcMajor ShareholderSell7,337$7.58$55,614.46View SEC Filing  
6/11/2013Vivo Ventures V, LlcMajor ShareholderSell13,727$7.80$107,070.60View SEC Filing  
5/16/2013Vivo Ventures Vii, LlcMajor ShareholderSell17,428$9.07$158,071.96View SEC Filing  
5/8/2013Leaf Ventures Ii L.P. NewMajor ShareholderSell200,000$8.58$1,716,000.00View SEC Filing  
1/25/2013Charles V Baltic IIIDirectorBuy10,200$6.04$61,608.00View SEC Filing  
12/21/2012Charles V Baltic IIIDirectorBuy3,500$7.18$25,130.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MEI Pharma (NASDAQ MEIP) News Headlines

Source:
DateHeadline
MEI Pharmas early-stage study of ME-344 in HER2-negative breast cancer to continue as planned; shares up 1% - Seeking AlphaMEI Pharma's early-stage study of ME-344 in HER2-negative breast cancer to continue as planned; shares up 1% - Seeking Alpha
seekingalpha.com - February 14 at 7:27 AM
MEI Pharma (MEIP) Says Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients ... - StreetInsider.comMEI Pharma (MEIP) Says Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients ... - StreetInsider.com
www.streetinsider.com - February 14 at 7:27 AM
MEI Pharma Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients with Breast CancerMEI Pharma Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients with Breast Cancer
finance.yahoo.com - February 13 at 3:28 PM
MEI Pharma (MEIP) Rating Increased to Hold at Zacks Investment ResearchMEI Pharma (MEIP) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - February 10 at 7:24 AM
MEI Pharma Reports Second Quarter Fiscal Year 2018 Results - PR Newswire (press release)MEI Pharma Reports Second Quarter Fiscal Year 2018 Results - PR Newswire (press release)
www.prnewswire.com - February 9 at 7:16 AM
MEI Pharma Reports Second Quarter Fiscal Year 2018 ResultsMEI Pharma Reports Second Quarter Fiscal Year 2018 Results
finance.yahoo.com - February 8 at 3:28 PM
Cann Reaffirms Buy Rating for MEI Pharma (MEIP)Cann Reaffirms Buy Rating for MEI Pharma (MEIP)
www.americanbankingnews.com - February 8 at 2:38 PM
Head-To-Head Contrast: Gemphire Therapeutics (GEMP) versus MEI Pharma (MEIP)Head-To-Head Contrast: Gemphire Therapeutics (GEMP) versus MEI Pharma (MEIP)
www.americanbankingnews.com - January 28 at 9:14 PM
MEI Pharma (MEIP) versus Its Competitors Head to Head AnalysisMEI Pharma (MEIP) versus Its Competitors Head to Head Analysis
www.americanbankingnews.com - January 14 at 11:30 AM
ETF Preview: ETFs, Futures Strain to Recover from Weakness Sparked by Bond-Market Woes; Street Mulls Jobless Claims, PPI DataETF Preview: ETFs, Futures Strain to Recover from Weakness Sparked by Bond-Market Woes; Street Mulls Jobless Claims, PPI Data
www.nasdaq.com - January 11 at 9:33 AM
MEI Pharma (MEIP) Granted FDA Clearance of Investigational New Drug Application for CDK Inhibitor VoruciclibMEI Pharma (MEIP) Granted FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib
www.streetinsider.com - January 8 at 5:42 PM
Critical Comparison: MEI Pharma (MEIP) & Its RivalsCritical Comparison: MEI Pharma (MEIP) & Its Rivals
www.americanbankingnews.com - January 3 at 11:30 PM
Head to Head Comparison: MEI Pharma (MEIP) & The CompetitionHead to Head Comparison: MEI Pharma (MEIP) & The Competition
www.americanbankingnews.com - January 1 at 7:28 AM
MEI Pharma (MEIP) vs. The Competition Critical ContrastMEI Pharma (MEIP) vs. The Competition Critical Contrast
www.americanbankingnews.com - December 29 at 7:24 PM
MEI Pharma (MEIP) versus The Competition Head-To-Head AnalysisMEI Pharma (MEIP) versus The Competition Head-To-Head Analysis
www.americanbankingnews.com - December 29 at 5:28 AM
ETFs with exposure to MEI Pharma, Inc. : December 25, 2017ETFs with exposure to MEI Pharma, Inc. : December 25, 2017
finance.yahoo.com - December 25 at 3:30 PM
MEI Pharma (MEIP) Says Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports - StreetInsider.comMEI Pharma (MEIP) Says Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports - StreetInsider.com
www.streetinsider.com - December 23 at 6:05 AM
MEI Pharmas (MEIP) Buy Rating Reaffirmed at CannMEI Pharma's (MEIP) Buy Rating Reaffirmed at Cann
www.americanbankingnews.com - December 21 at 4:28 PM
MEI Pharma (MEIP) Given a $7.00 Price Target at OppenheimerMEI Pharma (MEIP) Given a $7.00 Price Target at Oppenheimer
www.americanbankingnews.com - December 21 at 4:28 PM
MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific ReportsMEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports
finance.yahoo.com - December 21 at 9:14 AM
ETFs with exposure to MEI Pharma, Inc. : December 12, 2017ETFs with exposure to MEI Pharma, Inc. : December 12, 2017
finance.yahoo.com - December 12 at 6:01 PM
MEI Pharmas (MEIP) Buy Rating Reiterated at OppenheimerMEI Pharma's (MEIP) Buy Rating Reiterated at Oppenheimer
www.americanbankingnews.com - December 11 at 5:08 PM
MEI Pharma (MEIP) Receives "Buy" Rating from CannMEI Pharma (MEIP) Receives "Buy" Rating from Cann
www.americanbankingnews.com - December 11 at 9:00 AM
MEI Pharma (MEIP) Rating Lowered to Sell at ValuEngineMEI Pharma (MEIP) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 3 at 8:14 AM
MEI Pharma Inc (MEIP) Director Charles V. Baltic III Acquires 11,000 SharesMEI Pharma Inc (MEIP) Director Charles V. Baltic III Acquires 11,000 Shares
www.americanbankingnews.com - November 29 at 8:46 PM
Short Interest in MEI Pharma Inc (MEIP) Drops By 82.9%Short Interest in MEI Pharma Inc (MEIP) Drops By 82.9%
www.americanbankingnews.com - November 29 at 2:38 AM
MEI Pharma to Host Annual Meeting of StockholdersMEI Pharma to Host Annual Meeting of Stockholders
finance.yahoo.com - November 23 at 6:26 AM
ETFs with exposure to MEI Pharma, Inc. : November 20, 2017ETFs with exposure to MEI Pharma, Inc. : November 20, 2017
finance.yahoo.com - November 21 at 5:43 AM
MEI Pharma (MEIP) Presents At Stifel 2017 Healthcare Conference - SlideshowMEI Pharma (MEIP) Presents At Stifel 2017 Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 3:58 PM
Oppenheimer Holdings Brokers Increase Earnings Estimates for MEI Pharma, Inc. (MEIP)Oppenheimer Holdings Brokers Increase Earnings Estimates for MEI Pharma, Inc. (MEIP)
www.americanbankingnews.com - November 13 at 6:34 AM
MEI Pharma, Inc. :MEIP-US: Earnings Analysis: Q1, 2018 By the Numbers : November 9, 2017MEI Pharma, Inc. :MEIP-US: Earnings Analysis: Q1, 2018 By the Numbers : November 9, 2017
finance.yahoo.com - November 12 at 6:20 AM
ETFs with exposure to MEI Pharma, Inc. : November 10, 2017ETFs with exposure to MEI Pharma, Inc. : November 10, 2017
finance.yahoo.com - November 12 at 6:20 AM
Galectin Therapeutics (GALT) in Focus: Stock Moves 6.5% HigherGalectin Therapeutics (GALT) in Focus: Stock Moves 6.5% Higher
www.zacks.com - October 12 at 12:17 AM
Insmed (INSM) & MEI Pharma (MEIP) Head-To-Head ContrastInsmed (INSM) & MEI Pharma (MEIP) Head-To-Head Contrast
www.americanbankingnews.com - October 4 at 4:32 PM
AcelRx Pharmaceuticals (ACRX) in Focus: Stock Moves 19.6% HigherAcelRx Pharmaceuticals (ACRX) in Focus: Stock Moves 19.6% Higher
www.zacks.com - October 3 at 10:16 AM
MEI Pharma to Present at Cantor Fitzgerald Global Healthcare ConferenceMEI Pharma to Present at Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 6:16 AM
Featured Company News - Teva Pharmaceuticals Presents Outcome Measure Results from Phase-III Clinical Trials for the Potential of Fremanezumab to Treat Migraine PatientsFeatured Company News - Teva Pharmaceuticals Presents Outcome Measure Results from Phase-III Clinical Trials for the Potential of Fremanezumab to Treat Migraine Patients
finance.yahoo.com - September 13 at 6:29 AM
MEI Pharma (MEIP) Presents At 24th Annual NewsMakers in the Biotech Industry - SlideshowMEI Pharma (MEIP) Presents At 24th Annual NewsMakers in the Biotech Industry - Slideshow
seekingalpha.com - September 12 at 1:07 AM
Oppenheimer Holdings Equities Analysts Reduce Earnings Estimates for MEI Pharma, Inc. (MEIP)Oppenheimer Holdings Equities Analysts Reduce Earnings Estimates for MEI Pharma, Inc. (MEIP)
www.americanbankingnews.com - September 11 at 4:44 AM
FY2022 Earnings Estimate for MEI Pharma, Inc. Issued By Oppenheimer Holdings (MEIP)FY2022 Earnings Estimate for MEI Pharma, Inc. Issued By Oppenheimer Holdings (MEIP)
www.americanbankingnews.com - September 8 at 1:18 PM
MEI Pharma-Presage Biosciences on License Deal for Voruciclib - NasdaqMEI Pharma-Presage Biosciences on License Deal for Voruciclib - Nasdaq
www.nasdaq.com - September 8 at 3:43 AM
MEI Pharma-Presage Biosciences on License Deal for VoruciclibMEI Pharma-Presage Biosciences on License Deal for Voruciclib
finance.yahoo.com - September 7 at 5:01 AM
MEI Pharma, Inc. (MEIP) Issues Quarterly  Earnings ResultsMEI Pharma, Inc. (MEIP) Issues Quarterly Earnings Results
www.americanbankingnews.com - September 6 at 9:09 AM
Edited Transcript of MEIP earnings conference call or presentation 5-Sep-17 1:00pm GMTEdited Transcript of MEIP earnings conference call or presentation 5-Sep-17 1:00pm GMT
finance.yahoo.com - September 6 at 4:08 AM
12 Biggest Mid-Day Gainers For Tuesday | Benzinga - Benzinga12 Biggest Mid-Day Gainers For Tuesday | Benzinga - Benzinga
www.benzinga.com - September 5 at 11:06 PM
Earnings Scheduled For September 5, 2017 | Benzinga - BenzingaEarnings Scheduled For September 5, 2017 | Benzinga - Benzinga
www.benzinga.com - September 5 at 5:06 PM
MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK ... - PR Newswire (press release)MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK ... - PR Newswire (press release)
www.prnewswire.com - September 5 at 5:06 PM
MEI Pharma Reports Fiscal Year 2017 ResultsMEI Pharma Reports Fiscal Year 2017 Results
finance.yahoo.com - September 5 at 5:06 PM
MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK InhibitorMEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor
finance.yahoo.com - September 5 at 5:06 PM
MEI Pharma to Present at Two Upcoming Investor Conferences - PR Newswire (press release)MEI Pharma to Present at Two Upcoming Investor Conferences - PR Newswire (press release)
www.prnewswire.com - September 2 at 7:35 PM

SEC Filings

MEI Pharma (NASDAQ:MEIP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MEI Pharma (NASDAQ:MEIP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MEI Pharma (NASDAQ MEIP) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.